Abstract
Alzheimer’s disease with psychosis (AD+P) is a phenotypic variant of the disease which is associated with a much more rapid deterioration compared to Alzheimer’s disease without psychosis (AD-P). The neurobiological basis of AD+P is poorly understood. AD is thought to be a disease of the synapse, and our previous studies suggest that those with AD+P have a differentially affected synaptic proteome relative to those with AD-P. We previously demonstrated that multiple neuropathologies only account for approximately 18% of the variance in the occurrence of psychosis in AD. In this study, we utilized RNA-sequencing of dorsolateral prefrontal cortex (DLPFC) in a cohort of 80 AD cases to evaluate novel transcriptomic signatures that may confer risk of psychosis in AD. We found that AD+P was associated with a 9% reduction in excitatory neuron proportion compared to AD-P [Mean (SD) AD+P 0.295 (0.061); AD-P 0.324 (0.052), p = 0.026]. Network analysis identified altered expression of gene modules from protein ubiquitination, unfolded protein response, eukaryotic initiation factor 2 (EIF2) signaling and endoplasmic reticulum stress pathways in AD+P. Including cell type proportions and differentially expressed modules with neuropathology measures explained 67.5% of the variance in psychosis occurrence in our AD cohort.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH grants AG005133 (OLL, RAS, JK), AG066468 (OLL, RAS, JK) MH116046 (RAS, JK, MRD, MLM, YD, YW), K01 MH107756 (MLM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All subjects, when living provided informed consent to participate using protocols approved by the University of Pittsburgh Institutional Review Board. The study of postmortem tissue was approved by the University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available upon request
